Havetra

Havetra is a pharmaceutical product that contains the active ingredient enoxaparin sodium, a low‑molecular‑weight heparin, supplied in an injectable form for subcutaneous, intravenous, or haemodialysis administration. It is marketed in the European Union as a prescription‑only anticoagulant. Enoxaparin sodium works by enhancing antithrombin III activity, which reduces clot formation by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) in clinical practice for patients.

Havetra is indicated for several anticoagulation purposes in adult patients.

- Prevention of deep vein thrombosis (DVT) in patients undergoing surgery or prolonged immobilisation. - Treatment of acute DVT to reduce clot extension and recurrence. - Prevention and treatment of pulmonary embolism (PE) in at‑risk individuals. - Anticoagulation during haemodialysis to maintain circuit patency. - Prophylaxis of thromboembolic events in patients with acute medical illnesses.

Adverse reactions to Havetra may vary in frequency and severity.

Common: - Mild bruising, redness, or pain at the subcutaneous injection site. - Minor bleeding episodes such as occasional nosebleeds, gum bleeding, or easy bruising. - Small localized hematoma formation around the injection area. - Transient, mild elevations in liver transaminases observed in some patients.

Serious: - Life‑threatening bleeding, including intracranial hemorrhage, gastrointestinal bleeding, or postoperative hemorrhage. - Heparin‑induced thrombocytopenia (HIT) characterised by a rapid drop in platelet count and paradoxical clotting. - Severe hypersensitivity reactions, including rash, urticaria, angioedema, or anaphylactic shock. - Rare occurrences of hyperkalaemia or significant drops in blood pressure.

Before prescribing Havetra, clinicians should evaluate several safety considerations.

- Assess renal function; dose adjustment may be required in severe impairment. - Review patient history for active bleeding, recent surgery, or trauma. - Use cautiously in patients with a known history of heparin‑induced thrombocytopenia. - Monitor platelet counts regularly during therapy, especially after 5–10 days of treatment. - Evaluate concomitant use of other anticoagulants or antiplatelet agents for additive bleeding risk. - Consider pregnancy status; safety data are limited.

Havetra can interact with other medicines, affecting anticoagulant effect or bleeding risk.

Avoid: - Concurrent use with other injectable or oral anticoagulants (e.g., warfarin, dabigatran) unless specifically directed. - Combination with potent antiplatelet drugs such as clopidogrel or ticagrelor without monitoring.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin, which may increase minor bleeding. - Certain antibiotics (e.g., cefazolin) that can potentiate anticoagulant activity. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents that may elevate bleeding risk.